|
Gene: TG |
Gene summary for TG |
Gene summary. |
Gene information | Species | Human | Gene symbol | TG | Gene ID | 7038 |
Gene name | thyroglobulin | |
Gene Alias | AITD3 | |
Cytomap | 8q24.22 | |
Gene Type | protein-coding | GO ID | GO:0006575 | UniProtAcc | P01266 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7038 | TG | Adj_PTCwithHT_6 | Human | Thyroid | HT | 7.30e-105 | -2.11e+00 | 0.02 |
7038 | TG | Adj_PTCwithHT_8 | Human | Thyroid | HT | 6.03e-06 | -2.18e-01 | 0.0267 |
7038 | TG | PTCwithHT_1 | Human | Thyroid | HT | 1.56e-31 | -1.52e+00 | 0.0238 |
7038 | TG | PTCwithHT_6 | Human | Thyroid | HT | 1.38e-104 | -2.12e+00 | 0.02 |
7038 | TG | PTCwithHT_8 | Human | Thyroid | HT | 2.54e-58 | -1.07e+00 | 0.0351 |
7038 | TG | PTCwithoutHT_2 | Human | Thyroid | PTC | 3.80e-11 | -3.56e-01 | 0.0419 |
7038 | TG | PTCwithoutHT_7 | Human | Thyroid | PTC | 4.95e-19 | -8.43e-01 | 0.0381 |
7038 | TG | male-WTA | Human | Thyroid | PTC | 1.56e-05 | 1.85e-01 | 0.1037 |
7038 | TG | nodule-WTA | Human | Thyroid | goiters | 1.11e-15 | 2.90e-01 | 0.0534 |
7038 | TG | PTC01 | Human | Thyroid | PTC | 1.01e-25 | 2.49e+00 | 0.1899 |
7038 | TG | PTC03 | Human | Thyroid | PTC | 2.57e-11 | 1.84e+00 | 0.1784 |
7038 | TG | PTC04 | Human | Thyroid | PTC | 7.44e-08 | 1.70e+00 | 0.1927 |
7038 | TG | PTC05 | Human | Thyroid | PTC | 7.32e-32 | 2.88e+00 | 0.2065 |
7038 | TG | PTC06 | Human | Thyroid | PTC | 8.06e-54 | 4.16e+00 | 0.2057 |
7038 | TG | PTC07 | Human | Thyroid | PTC | 5.54e-48 | 2.79e+00 | 0.2044 |
7038 | TG | ATC08 | Human | Thyroid | ATC | 1.04e-55 | -1.49e+00 | 0.0541 |
7038 | TG | ATC09 | Human | Thyroid | ATC | 2.30e-54 | -2.31e+00 | 0.2871 |
7038 | TG | ATC11 | Human | Thyroid | ATC | 5.27e-20 | -2.31e+00 | 0.3386 |
7038 | TG | ATC12 | Human | Thyroid | ATC | 2.29e-129 | -2.31e+00 | 0.34 |
7038 | TG | ATC13 | Human | Thyroid | ATC | 7.68e-130 | -2.30e+00 | 0.34 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00455983 | Oral cavity | OSCC | regulation of fat cell differentiation | 77/7305 | 139/18723 | 6.36e-05 | 5.18e-04 | 77 |
GO:000689810 | Oral cavity | OSCC | receptor-mediated endocytosis | 125/7305 | 244/18723 | 6.56e-05 | 5.32e-04 | 125 |
GO:00072669 | Oral cavity | OSCC | Rho protein signal transduction | 76/7305 | 137/18723 | 6.64e-05 | 5.37e-04 | 76 |
GO:00020114 | Oral cavity | OSCC | morphogenesis of an epithelial sheet | 37/7305 | 57/18723 | 6.66e-05 | 5.38e-04 | 37 |
GO:00336194 | Oral cavity | OSCC | membrane protein proteolysis | 37/7305 | 57/18723 | 6.66e-05 | 5.38e-04 | 37 |
GO:19019843 | Oral cavity | OSCC | negative regulation of protein acetylation | 19/7305 | 24/18723 | 7.18e-05 | 5.67e-04 | 19 |
GO:20010213 | Oral cavity | OSCC | negative regulation of response to DNA damage stimulus | 49/7305 | 81/18723 | 7.27e-05 | 5.72e-04 | 49 |
GO:00074925 | Oral cavity | OSCC | endoderm development | 47/7305 | 77/18723 | 7.40e-05 | 5.81e-04 | 47 |
GO:190437716 | Oral cavity | OSCC | positive regulation of protein localization to cell periphery | 43/7305 | 69/18723 | 7.43e-05 | 5.81e-04 | 43 |
GO:00062789 | Oral cavity | OSCC | RNA-dependent DNA biosynthetic process | 46/7305 | 75/18723 | 7.44e-05 | 5.81e-04 | 46 |
GO:006157220 | Oral cavity | OSCC | actin filament bundle organization | 87/7305 | 161/18723 | 7.49e-05 | 5.84e-04 | 87 |
GO:00072196 | Oral cavity | OSCC | Notch signaling pathway | 92/7305 | 172/18723 | 7.84e-05 | 6.08e-04 | 92 |
GO:19032147 | Oral cavity | OSCC | regulation of protein targeting to mitochondrion | 30/7305 | 44/18723 | 8.41e-05 | 6.44e-04 | 30 |
GO:00066651 | Oral cavity | OSCC | sphingolipid metabolic process | 84/7305 | 155/18723 | 8.64e-05 | 6.61e-04 | 84 |
GO:0035067 | Oral cavity | OSCC | negative regulation of histone acetylation | 14/7305 | 16/18723 | 9.15e-05 | 6.93e-04 | 14 |
GO:007259316 | Oral cavity | OSCC | reactive oxygen species metabolic process | 122/7305 | 239/18723 | 9.73e-05 | 7.34e-04 | 122 |
GO:00140208 | Oral cavity | OSCC | primary neural tube formation | 55/7305 | 94/18723 | 9.87e-05 | 7.43e-04 | 55 |
GO:005110019 | Oral cavity | OSCC | negative regulation of binding | 87/7305 | 162/18723 | 1.00e-04 | 7.54e-04 | 87 |
GO:012003216 | Oral cavity | OSCC | regulation of plasma membrane bounded cell projection assembly | 98/7305 | 186/18723 | 1.00e-04 | 7.54e-04 | 98 |
GO:00905046 | Oral cavity | OSCC | epiboly | 25/7305 | 35/18723 | 1.02e-04 | 7.63e-04 | 25 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
COL1A1 | ITGA1_ITGB1 | COL1A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A2 | ITGA1_ITGB1 | COL1A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A1 | ITGA1_ITGB1 | COL4A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A2 | ITGA1_ITGB1 | COL4A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A1 | ITGA1_ITGB1 | COL6A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A2 | ITGA1_ITGB1 | COL6A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A3 | ITGA1_ITGB1 | COL6A3_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A1 | ITGA2_ITGB1 | COL1A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A2 | ITGA2_ITGB1 | COL1A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A1 | ITGA2_ITGB1 | COL4A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A2 | ITGA2_ITGB1 | COL4A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A1 | ITGA2_ITGB1 | COL6A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A2 | ITGA2_ITGB1 | COL6A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A3 | ITGA2_ITGB1 | COL6A3_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
LAMA2 | ITGA1_ITGB1 | LAMA2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMA4 | ITGA1_ITGB1 | LAMA4_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMB2 | ITGA1_ITGB1 | LAMB2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMB3 | ITGA1_ITGB1 | LAMB3_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMC1 | ITGA1_ITGB1 | LAMC1_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMC2 | ITGA1_ITGB1 | LAMC2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TG | SNV | Missense_Mutation | rs201480815 | c.3416N>T | p.Ser1139Leu | p.S1139L | P01266 | protein_coding | tolerated(0.14) | benign(0) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TG | SNV | Missense_Mutation | c.4662G>T | p.Trp1554Cys | p.W1554C | P01266 | protein_coding | deleterious(0.01) | benign(0.123) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||
TG | SNV | Missense_Mutation | c.4882N>T | p.Asp1628Tyr | p.D1628Y | P01266 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
TG | SNV | Missense_Mutation | c.3133N>A | p.Gly1045Arg | p.G1045R | P01266 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
TG | SNV | Missense_Mutation | c.5223N>C | p.Gln1741His | p.Q1741H | P01266 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
TG | SNV | Missense_Mutation | rs773795717 | c.4645C>T | p.Arg1549Trp | p.R1549W | P01266 | protein_coding | deleterious(0.05) | benign(0.232) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
TG | SNV | Missense_Mutation | novel | c.1093N>A | p.Ala365Thr | p.A365T | P01266 | protein_coding | tolerated(0.44) | benign(0) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | rs146594373 | c.4268N>A | p.Arg1423His | p.R1423H | P01266 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
TG | SNV | Missense_Mutation | c.746G>A | p.Gly249Asp | p.G249D | P01266 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | ||
TG | SNV | Missense_Mutation | c.3746N>T | p.Cys1249Phe | p.C1249F | P01266 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | RETINOIDS | 12182039 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | FDG | FLUDEOXYGLUCOSE-F18 | 10452315 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | BISPECIFIC ANTIBODY | 10433080 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PHENYTOIN | PHENYTOIN | 3935423 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PREDNISONE | PREDNISONE | 2745931 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | ALL-TRANS-RETINOIC ACID | 10946899 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | TGFBETA1 | 10770487,10194419 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | RETINOIC ACID | 11563543 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PREDNISOLONE | PREDNISOLONE | 3427792,8636270 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | AMIODARONE | AMIODARONE | 8778159 |
Page: 1 2 3 4 |